NCT03682744撤回1 期
Immunotherapy for Peritoneal Carcinomatosis (IPC) - A Phase I Study of the Safety and Efficacy of Anti-CEA CAR-T Cell Intraperitoneal Infusions for Treatment of CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites
适应症
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 4
- 主要终点
- Safety of Intraperitoneal CAR-T Cell Infusions as Measured by Number of Participants with Adverse Events
研究概览
简要总结
This is an open-label, dose-escalation, phase I trial of the safety and efficacy of anti-CEA intraperitoneal CAR-T infusions for treatment in patients with CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites.
详细描述
Patients undergo leukapheresis from which peripheral blood mononuclear cells are purified. T cells are activated and then re-engineered to express chimeric antigen receptors (CARs) specific for CEA. Cells are expanded in culture and returned to the patient by intraperitoneal infusion at specific cell doses. One anti-CEA CAR-T dose per patient is planned. Additional cycles may be administered at the discretion of the principal investigator. Normal peritoneal and tumor biopsies will be obtained at the time of the CAR-T infusion, on the final day of the treatment period, and during reporting interval #3.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age ≥ 18 years.
- •Must have documented CEA+ carcinomatosis or malignant ascites as demonstrated by an elevated serum CEA level (≥ 10 ng/mL) or immunohistochemistry on a biopsy or cytologic specimen (archived tissue is acceptable), for determination of CEA expression. Primary tumor may be intact and limited liver and/or lung disease permitted.
- •Must have at least evaluable disease by physical examination, serum tumor markers, radiologic assessment, tumor markers, or laparoscopic visual assessment.
- •Have a life-expectancy ≥ 12 weeks and ECOG performance status ≤
- •May have low volume of liver metastases defined as < 50% replacement of the liver volume by metastatic disease, as long as all other eligibility criteria are satisfied.
- •Be willing and able to comply with the study schedule and all other protocol requirements.
排除标准
- •Female patients of childbearing age will be tested for pregnancy. Pregnant patients will be excluded from the study. Males who are actively seeking to have children will be made aware of the unknown risks of this study protocol on human sperm and the need to practice birth control.
- •Received an investigational study drug within 14 days of leukapheresis or 28 days before receiving first dose of study drug. Exceptions may be granted with medical monitor approval.
- •Received any approved anticancer medication within 14 days of leukapheresis or 14 days before receiving the first dose of study drug. Exceptions may be granted with medical monitor approval.
- •Have any unresolved toxicity > Grade 2 from previous anticancer therapy, except for stable chronic toxicities (≤ Grade 3) that are not expected to resolve.
- •Have a history of histologically confirmed metastases outside the peritoneal cavity, lungs, or liver.
- •Have high volume lung or liver metastases, defined as >5 lung lesions greater than 1 cm in size or ≥ 50% replacement the liver volume by metastatic disease.
- •Received CAR-T, CAR-T cell line, CAR-NK, CAR-pNK, or CAR-NK cell line therapies.
- •Have any of the following laboratory results at Screening (Screening volumes must be independent of blood product treatment):
- •Hemoglobin ≤ 8.0 g/dL
- •Platelet count < 50 × 109/L
- •Absolute neutrophil count (ANC) < 1.0 × 109/L
- •Untreated or ongoing intra-abdominal infection or bowel obstruction.
- •Have any of the following laboratory results at Screening, regardless of causality:
- •Serum creatinine ≥ 3.0, or estimated creatinine clearance ≤ 30 mL/min and not dialysis dependent
- •Aspartate aminotransferase (AST) ≥ 4 × upper limit of normal (ULN) and total bilirubin ≥ 2.0 mg/dL (except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome).
- •Have human immunodeficiency virus (HIV) infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia, or are at risk for HBV reactivation (at risk for HBV reactivation is defined as being HBsAg positive, or anti-HBc-antibody positive), or are positive for HBV deoxyribonucleic acid (DNA). HCV ribonucleic acid (RNA) must be undetectable by laboratory test.
- •Are pregnant or breastfeeding.
- •Have active bacterial, viral, or fungal infection: patients with ongoing use of prophylactic antibiotics, antiviral agents, or antifungal agents remain eligible as long as there is no evidence of active infection.
- •Has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from participating in the study.
- •Has any condition, including the presence of laboratory abnormalities that places the patient at an unacceptable risk if the patient was to participate in the study.
- •Left ventricular ejection fraction (LVEF) < 40%
结局指标
主要结局
Safety of Intraperitoneal CAR-T Cell Infusions as Measured by Number of Participants with Adverse Events
时间窗: 16 weeks
To determine the safety and maximum tolerated dose (MTD) following intraperitoneal infusion(s) of anti-CEA CAR-T cells for inoperable CEA+ peritoneal metastases or malignant ascites.
次要结局
- Progression-Free Survival(20 weeks)
- Bowel Obstruction Free Survival(20 weeks)
- Overall Survival(20 weeks)
- Changes in Quality of Life(20 weeks)
- Radiographic treatment response by PET(20 weeks)
- Serologic response rates(20 weeks)
- Response by the Peritoneal Carcinomatosis Index (PCI)(16 weeks)
- Radiographic treatment response by MRI(20 weeks)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Feasibility of Intraperitoneal Chemotherapy in the Surgical Treatment of Colon Cancer cT4Colon CancerNCT03561948State Scientific Centre of Coloproctology, Russian Federation90
Unknown
不适用
Prospective Intraperitoneal Chemotherapy in Carcinomatosis Cohort StudyPeritoneal CarcinomatosisNCT03124394Kantonsspital Winterthur KSW100
招募中
1 期
A Study of AK131 in Patients With Advanced Solid TumorsSolid TumorNCT06166888Akeso130
Unknown
3 期
Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric CancerAdvanced Gastric Cancer With Serosal InvasionNCT02205008Kyungpook National University Hospital230
招募中
1 期
Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic NivolumabSolid TumorMetastases to Soft TissueNCT03707808Universitair Ziekenhuis Brussel18